Fourteen patients with genotypic ADV resistance were excluded due to potential cross resistance (evaluated separately) and 6 due to non-compliance to TDF.

• 14位有基因型ADV（阿得福韦）抵抗的患者由于潜在的交叉抗药性被排除在外（分离评估），另有6位患者则是由于对TDF不耐受。